tiprankstipranks
Numinus Wellness Stands Firm Despite FDA Setback
Company Announcements

Numinus Wellness Stands Firm Despite FDA Setback

Story Highlights

Numinus Wellness (TSE:NUMI) has released an update.

Don't Miss Our Christmas Offers:

Numinus Wellness Inc. has addressed the FDA’s refusal to approve MDMA-assisted therapy for PTSD by reiterating their commitment to advancing psychedelic therapies and continuing their pursuit of profitability through existing operations. Despite the setback, Numinus remains confident in the future efficacy of MDMA and other psychedelic treatments, and highlights their continued leadership in providing mental health care and conducting clinical research.

For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskNuminus Wellness Sells Clinics, Focuses on Tech Solutions
TipRanks Canadian Auto-Generated NewsdeskNuminus Wellness Faces Trade Restrictions Amid Filing Delays
Brian AndersonNUMI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App